Rivaroxaban
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='5vof' size='350' side='right' caption='DesGla-XaS195A Bound to Aptamer 11F7t and Rivaroxaban' scene='95/954035/Cv/1'> | <StructureSection load='5vof' size='350' side='right' caption='DesGla-XaS195A Bound to Aptamer 11F7t and Rivaroxaban' scene='95/954035/Cv/1'> | ||
| - | <scene name='95/954035/Cv/2'>Rivaroxaban</scene>, sold under the brand name '''Xarelto''' among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. Rivaroxaban inhibits both free and bound [[Factor Xa]] in the prothrombinase complex. It is a selective direct factor Xa inhibitor with an onset of action of 2.5 to 4 hours. Inhibition of Factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. It allows predictable anticoagulation and dose adjustments and routine coagulation monitoring; dietary restrictions are not needed. See also [https://en.wikipedia.org/wiki/Rivaroxaban Rivaroxaban]. | + | <scene name='95/954035/Cv/2'>Rivaroxaban</scene>, sold under the brand name '''Xarelto''' among others, is an [[Anticoagulants|anticoagulant medication]] (blood thinner) used to treat and prevent blood clots. Rivaroxaban inhibits both free and bound [[Factor Xa]] in the prothrombinase complex. It is a selective direct factor Xa inhibitor with an onset of action of 2.5 to 4 hours. Inhibition of Factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. It allows predictable anticoagulation and dose adjustments and routine coagulation monitoring; dietary restrictions are not needed. See also [https://en.wikipedia.org/wiki/Rivaroxaban Rivaroxaban]. |
<scene name='95/954035/Cv/5'>Rivaroxaban binding site</scene>. See also [[Apixaban]]. | <scene name='95/954035/Cv/5'>Rivaroxaban binding site</scene>. See also [[Apixaban]]. | ||
Current revision
| |||||||||||
